424 related articles for article (PubMed ID: 22086865)
21. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
22. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
24. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
27. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
28. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
29. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
30. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
31. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
32. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
33. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
34. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.
Tefferi A; Mudireddy M; Gangat N; Hanson CA; Ketterling RP; Pardanani A; Nagorney DM
Am J Hematol; 2017 Nov; 92(11):1187-1192. PubMed ID: 28782256
[TBL] [Abstract][Full Text] [Related]
36. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
37. Prognostication in primary myelofibrosis.
Cervantes F; Pereira A
Curr Hematol Malig Rep; 2012 Mar; 7(1):43-9. PubMed ID: 22072485
[TBL] [Abstract][Full Text] [Related]
38. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI; Levine RL
Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
[TBL] [Abstract][Full Text] [Related]
39. How I treat myelofibrosis.
Tefferi A
Blood; 2011 Mar; 117(13):3494-504. PubMed ID: 21200024
[TBL] [Abstract][Full Text] [Related]
40. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]